Depletion of TRAMs before tumor engraftment can lead to lower tumor burden, reduced FOXP3+ Tregs, and increased IFN-γ+ CD8 T cells, indicating TRAMs support the early stage of NSCLC development (39). This evidence concerns the gene CD8A and neoplasm.